272 related articles for article (PubMed ID: 21368721)
1. Positive allosteric modulators of type 5 metabotropic glutamate receptors (mGluR5) and their therapeutic potential for the treatment of CNS disorders.
Cleva RM; Olive MF
Molecules; 2011 Mar; 16(3):2097-106. PubMed ID: 21368721
[TBL] [Abstract][Full Text] [Related]
2. mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning.
Ayala JE; Chen Y; Banko JL; Sheffler DJ; Williams R; Telk AN; Watson NL; Xiang Z; Zhang Y; Jones PJ; Lindsley CW; Olive MF; Conn PJ
Neuropsychopharmacology; 2009 Aug; 34(9):2057-71. PubMed ID: 19295507
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of metabotropic glutamate receptor allosteric modulators: structural basis and therapeutic potential for CNS disorders.
Gregory KJ; Noetzel MJ; Niswender CM
Prog Mol Biol Transl Sci; 2013; 115():61-121. PubMed ID: 23415092
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity.
Rodriguez AL; Grier MD; Jones CK; Herman EJ; Kane AS; Smith RL; Williams R; Zhou Y; Marlo JE; Days EL; Blatt TN; Jadhav S; Menon UN; Vinson PN; Rook JM; Stauffer SR; Niswender CM; Lindsley CW; Weaver CD; Conn PJ
Mol Pharmacol; 2010 Dec; 78(6):1105-23. PubMed ID: 20923853
[TBL] [Abstract][Full Text] [Related]
5. Effect of Novel Allosteric Modulators of Metabotropic Glutamate Receptors on Drug Self-administration and Relapse: A Review of Preclinical Studies and Their Clinical Implications.
Caprioli D; Justinova Z; Venniro M; Shaham Y
Biol Psychiatry; 2018 Aug; 84(3):180-192. PubMed ID: 29102027
[TBL] [Abstract][Full Text] [Related]
6. Ionotropic and metabotropic glutamate receptor structure and pharmacology.
Kew JN; Kemp JA
Psychopharmacology (Berl); 2005 Apr; 179(1):4-29. PubMed ID: 15731895
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine.
Clifton NE; Morisot N; Girardon S; Millan MJ; Loiseau F
Psychopharmacology (Berl); 2013 Feb; 225(3):579-94. PubMed ID: 22983144
[TBL] [Abstract][Full Text] [Related]
8. Metabotropic Glutamate Receptors in Central Nervous System Diseases.
Golubeva AV; Moloney RD; O'Connor RM; Dinan TG; Cryan JF
Curr Drug Targets; 2016; 17(5):538-616. PubMed ID: 25777273
[TBL] [Abstract][Full Text] [Related]
9. Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors.
Marino MJ; Conn PJ
Curr Opin Pharmacol; 2006 Feb; 6(1):98-102. PubMed ID: 16368268
[TBL] [Abstract][Full Text] [Related]
10. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function.
Noetzel MJ; Rook JM; Vinson PN; Cho HP; Days E; Zhou Y; Rodriguez AL; Lavreysen H; Stauffer SR; Niswender CM; Xiang Z; Daniels JS; Jones CK; Lindsley CW; Weaver CD; Conn PJ
Mol Pharmacol; 2012 Feb; 81(2):120-33. PubMed ID: 22021324
[TBL] [Abstract][Full Text] [Related]
11. Discovery of positive allosteric modulators of metabotropic glutamate receptor subtype 5 (mGluR5).
Williams DL; Lindsley CW
Curr Top Med Chem; 2005; 5(9):825-46. PubMed ID: 16178729
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.
Dekundy A; Gravius A; Hechenberger M; Pietraszek M; Nagel J; Tober C; van der Elst M; Mela F; Parsons CG; Danysz W
J Neural Transm (Vienna); 2011 Dec; 118(12):1703-16. PubMed ID: 21161716
[TBL] [Abstract][Full Text] [Related]
13. The role of metabotropic glutamate receptor 5 in learning and memory processes.
Simonyi A; Schachtman TR; Christoffersen GR
Drug News Perspect; 2005; 18(6):353-61. PubMed ID: 16247513
[TBL] [Abstract][Full Text] [Related]
14. Negative allosteric modulators of group II metabotropic glutamate receptors: A patent review (2015 - present).
Qunies AM; Emmitte KA
Expert Opin Ther Pat; 2021 Aug; 31(8):687-708. PubMed ID: 33719801
[TBL] [Abstract][Full Text] [Related]
15. Co-operative binding assay for the characterization of mGlu4 allosteric modulators.
Poutiainen P; Kil KE; Zhang Z; Kuruppu D; Tannous B; Brownell AL
Neuropharmacology; 2015 Oct; 97():142-8. PubMed ID: 26025660
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological modulation of metabotropic glutamate receptor subtype 5 and 7 impairs extinction of social fear in a time-point-dependent manner.
Slattery DA; Neumann ID; Flor PJ; Zoicas I
Behav Brain Res; 2017 Jun; 328():57-61. PubMed ID: 28392321
[TBL] [Abstract][Full Text] [Related]
17. Allosteric modulation of Class C GPCRs: a novel approach for the treatment of CNS disorders.
Engers DW; Lindsley CW
Drug Discov Today Technol; 2013; 10(2):e269-76. PubMed ID: 24050278
[TBL] [Abstract][Full Text] [Related]
18. Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia.
Matosin N; Newell KA
Neurosci Biobehav Rev; 2013 Mar; 37(3):256-68. PubMed ID: 23253944
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in positive allosteric modulators of metabotropic glutamate receptors.
Shipe WD; Wolkenberg SE; Williams DL; Lindsley CW
Curr Opin Drug Discov Devel; 2005 Jul; 8(4):449-57. PubMed ID: 16022181
[TBL] [Abstract][Full Text] [Related]
20. Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).
Stauffer SR
ACS Chem Neurosci; 2011 Aug; 2(8):450-70. PubMed ID: 22860171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
